Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Argus Health
McKinsey
Chubb
US Department of Justice
Farmers Insurance
Teva
UBS
Johnson and Johnson

Generated: September 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020592

« Back to Dashboard

NDA 020592 describes ZYPREXA, which is a drug marketed by Lilly and Eli Lilly Co and is included in four NDAs. It is available from eight suppliers. There is one patent protecting this drug. Additional details are available on the ZYPREXA profile page.

The generic ingredient in ZYPREXA is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.
Summary for 020592
Tradename:ZYPREXA
Applicant:Lilly
Ingredient:olanzapine
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020592
Suppliers and Packaging for NDA: 020592
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZYPREXA olanzapine TABLET;ORAL 020592 NDA Eli Lilly and Company 0002-4112 0002-4112-30 30 TABLET in 1 BOTTLE (0002-4112-30)
ZYPREXA olanzapine TABLET;ORAL 020592 NDA Eli Lilly and Company 0002-4115 0002-4115-30 30 TABLET in 1 BOTTLE (0002-4115-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2.5MG
Approval Date:Sep 30, 1996TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Sep 30, 1996TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength7.5MG
Approval Date:Sep 30, 1996TE:ABRLD:Yes

Expired US Patents for NDA 020592

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-002 Sep 30, 1996 ➤ Sign Up ➤ Sign Up
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-006 Sep 9, 1997 ➤ Sign Up ➤ Sign Up
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-006 Sep 9, 1997 ➤ Sign Up ➤ Sign Up
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-002 Sep 30, 1996 ➤ Sign Up ➤ Sign Up
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-005 Sep 9, 1997 ➤ Sign Up ➤ Sign Up
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-006 Sep 9, 1997 ➤ Sign Up ➤ Sign Up
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-002 Sep 30, 1996 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Citi
Chinese Patent Office
QuintilesIMS
Queensland Health
Cipla
Moodys
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.